Skip to content
Back to meeting Original
Mustafa Özdoğan, MD· @ozdogan_md · X·· 1 day agoScore70
Body

4 studies I’m watching today at #ESMO26

Presidential Symposium II (16:30 CET): KRAScendo 1, SAFFRON, CLARITY-Gastric 01 and HARMONi-GI1.
Which one are you waiting for?
I’ll post notes right after each LBA.
#Oncology

54 views · 1 like · 1 repost · 0 replies

Conference abstracts
2954TIPNCT07431281NCT07431281NCT07431281matched by Oesophagogastric cancer

CLARITY-Gastric 02: A randomised phase 3 study of sonesitatug vedotin (Sone-Ve) and capecitabine with or without rilvegostomig in Claudin18.2 positive (CLDN18.2+) advanced or metastatic gastric, gastroesophageal junction, or oesophageal ade

https://esmocongress.esmo.org

Source: Mustafa Özdoğan, MD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.